TME Pharma N.V. (0N6A)

Overview

TME Pharma N.V. is a clinical-stage biopharmaceutical company dedicated to revolutionizing cancer treatment through its innovative research and development in Germany. As a pioneer in the field, it leverages the Spiegelmer platform to craft proprietary therapeutics aimed at combatting various forms of cancer. The company, initially known as NOXXON Pharma N.V., underwent a rebranding to TME Pharma N.V. in July 2022, reflecting its focused direction and ambition in the oncology space. Founded in 1997 and with its headquarters in Berlin, Germany, TME Pharma has positioned itself as a key player in the cancer research industry, emphasizing the development of combination therapies for a range of cancer indications.

Products and Services

• NOX-A12 - A lead cancer drug candidate designed by TME Pharma N.V., NOX-A12 is at the forefront of the company’s pipeline. It is currently under development as a combination therapy aimed at targeting various cancer indications, including metastatic pancreatic and colorectal cancer, as well as glioblastoma. This innovative therapeutic approach highlights TME Pharma's commitment to addressing hard-to-treat cancers and improving patient outcomes through combination therapy strategies.
• NOX-E36 - Another significant product candidate from TME Pharma N.V. is NOX-E36, which has successfully completed a Phase 1/2a clinical trial. This drug candidate is being developed for the treatment of diabetic nephropathy, showcasing the company's versatile approach not only in oncology but also in addressing complex metabolic disorders like diabetes. NOX-E36 represents TME Pharma's dedication to expanding its therapeutic pipeline beyond cancer, providing hope for patients with diabetic nephropathy.